Optic atrophies in metabolic disorders

被引:14
作者
Huizing, M [1 ]
Brooks, BP
Anikster, Y
机构
[1] NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA
[2] NEI, NIH, Bethesda, MD 20892 USA
[3] Safra Children Hosp, Metab Dis Unit, Sheba Med Ctr, Tel Hashomer, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
eye; inborn error of metabolism; myelination; oligodendrocyte; ophthalmology; optic nerve pallor; optic neuropathy; reactive oxygen species; retina; retinal ganglion cell;
D O I
10.1016/j.ymgme.2005.07.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Optic nerve involvement in metabolic disorders often results from apoptosis of cells that form or support the optic nerve, the retinal ganglion cell (RGC) axons, the myelin-forming oligodendrocytes, or the supporting vascular system. Given their high energy demands and the long course of their axons, RGCs are particularly sensitive to intracellular metabolic defects. Defects in energy metabolism, formation of reactive oxygen species, and storage of metabolites can all cause apoptosis of RGCs, decreased myelin formation of oligodendrocytes and increased pressure on the optic nerve. Clinically, the loss of RGC axons manifests as pale optic nerves. In general, the ophthalmologist can identify the underlying cause of an optic atrophy by careful examination, neuro-imaging, and family history. In some cases, however, the diagnosis proves elusive. In these instances, and especially when optic atrophy is accompanied by other systemic involvement, a metabolic disorder should be considered. Here, we review the underlying mechanisms of optic atrophy and its significance in metabolic disorders. Early identification of optic atrophy aids the diagnosis and subsequent management of the underlying condition, including anticipation of symptoms, genetic counseling, and possible therapeutic interventions. For many metabolic disorders, molecular testing is available. Published by Elsevier Inc.
引用
收藏
页码:51 / 60
页数:10
相关论文
共 103 条
[41]  
GARCIN R., 1961, REV NEUROL [PARIS], V104, P373
[42]   Metachromatic leukodystrophy: consequences of sulphatide accumulation [J].
Gieselmann, V ;
Franken, S ;
Klein, D ;
Mansson, JE ;
Sandhoff, R ;
Rauch, RL ;
Hartmann, D ;
Saravanan, VPM ;
De Deyn, PP ;
D'Hooge, R ;
Van der Linden, AM ;
Schaeren-Wiemers, N .
ACTA PAEDIATRICA, 2003, 92 :74-79
[43]   The pathogenesis of glycosphingolipid storage disorders [J].
Ginzburg, L ;
Kacher, Y ;
Futerman, AH .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2004, 15 (04) :417-431
[44]  
GLASER JS, 1990, NEUROOPHTHALMOLOGY, P61
[45]   Current state of clinical and morphological features in human NCL [J].
Goebel, HH ;
Wisniewski, KE .
BRAIN PATHOLOGY, 2004, 14 (01) :61-69
[46]  
Gordon N, 2001, Eur J Paediatr Neurol, V5, P65, DOI 10.1053/ejpn.2001.0467
[47]   Loss of the intermembrane space protein Mgm1/OPA1 induces swelling and localized constrictions along the lengths of mitochondria [J].
Griparic, L ;
van der Wel, NN ;
Orozco, IJ ;
Peters, PJ ;
van der Bliek, AM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (18) :18792-18798
[48]   MOLECULAR AND METABOLIC BASIS FOR THE METABOLIC DISORDER NORMOTRIGLYCERIDEMIC ABETALIPOPROTEINEMIA [J].
HARDMAN, DA ;
PULLINGER, CR ;
HAMILTON, RL ;
KANE, JP ;
MALLOY, MJ .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) :1722-1729
[49]   Leber hereditary optic neuropathy mitochondrial mutations and degeneration of the optic nerve [J].
Howell, N .
VISION RESEARCH, 1997, 37 (24) :3495-3507
[50]   Optic nerve atrophy in propionic acidemia [J].
Ianchulev, T ;
Kolin, T ;
Moseley, K ;
Sadun, A .
OPHTHALMOLOGY, 2003, 110 (09) :1850-1854